|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||30.10 - 30.25|
|52 Week Range||27.60 - 36.82|
|PE Ratio (TTM)||21.20|
|Forward Dividend & Yield||1.03 (3.28%)|
|1y Target Est||N/A|
An experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced, aggressive blood cancer live significantly longer than the standard treatment alone, according to data from a mid-stage trial released at a medical meeting on Sunday. In the trial of 80 patients with diffuse large B-cell lymphoma (DLBCL) whose disease had progressed despite several treatment regimens, the addition of Roche's polatuzumab vedotin raised the complete response rate to 40 percent.
Puma's (PBYI) shares skyrocket in the year so far on the approval of its cancer drug Nerlynx in the United States coupled with strategic collaborations.
Prosecutors in Rome have been looking into charges the two companies colluded to discredit eye disease drug Avastin by emphasizing its potential side effects in order to boost sales of Lucentis, a more expensive alternative which offers similar treatment. Both Avastin and Lucentis are manufactured by Roche but Lucentis is marketed by Novartis outside the United States.
Scientists at Swiss drugmaker Roche said on Friday they may have discovered why some tumours resist new immunotherapy drugs as well as a possible means of turning the tables to incite a T-cell attack. The company has been analysing biomarkers in 300 patients from its Imvigour 210 bladder cancer study to learn more about those who did not respond to its Tecentriq treatment, it said at the European Society for Medical Oncology meeting in Geneva. Its doctors now believe some tumours that express high levels of a protein called TGF-beta develop a fortified wall.
Roche Holding said its immunotherapy drug Tecentriq slowed the progression of lung cancer and helped patients live longer in a late-stage study, bolstering the Swiss drugmaker’s defense against a wave ...
Roche's Tecentriq plus older drugs doubled the percentage of lung cancer patients surviving a year without disease progression.
Roche (RHHBY) announced interim results from the phase III IMpower150 study of Tecentriq and Avastin plus chemotherapy in people with advanced form of lung cancer.
Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts on Thursday labelled unprecedented. Its shares retreated, however, as analysts said uncertainty lingers over whether the result is sufficient to give the Swiss drugmaker a jump on rivals Merck & Co and Bristol-Myers Squibb, whose immunotherapy sales dwarf Roche's own.
Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts labelled unprecedented. Thirty seven percent of patients in a closely watched clinical trial who received Tecentriq, Avastin and chemotherapy reached the one-year mark without their cancer progressing (PFS), according to data released on Thursday. For patients getting only Avastin and chemotherapy, that fell to 18 percent.
The FDA grants priority review to Clovis' (CLVS) supplemental new drug application for its marketed drug, Rubraca's label expansion as a maintenance treatment for ovarian cancer.
Roche (RHHBY) announced that the FDA converted accelerated approval for Avastin to full approval for the patients previously treated for aggressive form of brain cancer.
After lagging rivals in cancer immunotherapies, Swiss drugmaker Roche (ROG.S) hopes to leap-frog into the lead in the biggest market, tackling previously untreated lung cancer. "We have a real chance to be at the forefront here," Chief Executive Severin Schwan said on Wednesday. At the same time he warned many investors would lose money across the industry as a large proportion of the hundreds of cancer trials now underway failed, leaving just a few winners.
AbbVie (ABBV) J&J's combination study evaluating Imbruvica in Waldenstrom's macroglobulinemia (WM), a rare form of non-Hodgkin's lymphoma, meets primary endpoint.
Mylan (MYL) receives approval for its biosimilar of breast cancer drug, Herceptin. Amazon is reportedly in talks with Mylan and another generic manufacturer about a potential entry in distribution of drugs.
ImmunoGen's (IMGN) shares shoot up in the year so far on rapid pipeline progress plus positive study data and strategic collaborations.
This week the European Commission granted approval to Zejula for ovarian cancer and for label expansion of Tasigna in first-line Ph+ chronic myeloid leukemia.
Key highlights this week include the FDA approval of GlaxoSmithKline (GSK) and J&J's new HIV drug and study data from Roche.
With the emergence of complex and transmittable diseases worldwide, In Vitro Diagnostic within the MedTech space is currently in the spotlight.
In September 2017, the FDA approved Merck’s (MRK) Keytruda for the treatment of individuals with relapsing or recurrent metastatic GEJ (gastroesophageal junction) adenocarcinoma with PDL11-expressing tumors, ...
Roche Holding AG, facing pressure in Europe as cheaper biosimilars of its three biggest cancer medicines chew away at its revenue, sued to block Pfizer Inc. from selling a copy of its breast-cancer drug ...
Roche is now a real competitor with a potential first treatment in advanced lung cancer, an analyst said Monday.